Tweenvest Stocks

Mabion S.A. (WSE: MAB)

Health Care · Biotechnology · PL

zł8.07

+0.88% today · -3.9% 1Y

Mabion S.A. (WSE: MAB) operates in the Biotechnology industry within the Health Care sector. The company is valued at $33.59M and employs 202 people.

Over the last twelve months the share price has lost 3.9%, trading between 6.70 and 10.00.

Tweenvest scores Mabion S.A. across four factors: quality 47/100, value 67/100. Its strongest factor is value.

MAB price history

Not enough price history to draw a chart yet.

Key figures

Market cap
$33.59M
Revenue (TTM)
$4.68M
P/E
—
EPS
-3.50
Dividend yield
—
Beta (5Y)
0.42
52-week high
zł10.00
52-week low
zł6.70
Avg volume (3M)
—
Shares outstanding
16.16M
Employees
202
Next earnings
—

About Mabion S.A.

Mabion S.A. is a Polish biopharmaceutical firm dedicated to pioneering the development of biological drugs, primarily leveraging monoclonal antibody technology. The company oversees the full spectrum from research and development to the manufacturing and commercialization of therapies designed to combat a wide range of diseases, including neoplastic (cancer), autoimmune, metabolic, and neurological disorders. Key products in its portfolio include MabionCD20 and MabionHER2. Established in 2007, Mabion S.A. maintains its headquarters in Konstantynów Lódzki, Poland.

ISIN
PLMBION00016
Founded
2007
Listed since
Aug 10, 2010
Exchange
Warsaw Stock Exchange
Currency
PLN
CompanyMarket capPriceDay
Edesa Biotech, Inc.NasdaqCM: EDSA$34.72M$2.57-26.78%
Biomark Diagnostics Inc.DB: 20B$34.02M€0.28-4.70%
CervoMed Inc.NasdaqCM: CRVO$33.87M$2.24-30.43%
Cell Source, Inc.OTCPK: CLCS$33.63M$0.49-10.45%
Genetics Generation Advancement Corp.TPEX: 4160$33.50MNT$38.80-0.26%
Vivoryon Therapeutics N.V.ENXTAM: VVY$32.98M€0.99-5.71%
QuantaMatrix Inc.KOSDAQ: A317690$32.77M₩2,170.00-6.26%
Kringle Pharma, Inc.TSE: 4884$32.60M¥614.00-4.81%

Browse every Biotechnology company →

Figures last refreshed Oct 18, 2026.